valuation

Valuation analysis applies multiple methodologies — DCF, comparable companies, scenario modeling, and reverse-engineering — to triangulate JPMorgan Chase & Co's intrinsic value. Current price: $286.56. Our probability-weighted estimate: $265.00 (-6.5%).

prob-wtd fv
$298
vs $286.56 current
p/e ratio
14.2x
vs 12x sector avg
p/b ratio
2.1x
vs 1.3x bac, 1.0x c
roe spread
630 bps
15.7% roe vs 9.4% coe
upside/downside
+5.1%
to $298 prob-wtd target
The DCF model's negative output ($265) is a methodological artifact, not a signal. Banks generate value through earnings and book value growth, not free cash flow; the -$147.78B operating cash flow reflects regulatory cash requirements and lending activity. The market's $286.56 price at 14.2x earnings and 2.1x book implicitly assumes mid-teens ROTCE persistence—achievable but demanding continued execution on the $15B+ technology investment program.
valuation range by method

dcf & earnings-based model assumptions

bank-adjusted

Standard DCF is inappropriate for JPM. The model output of $265 per share reflects fundamental misspecification: banks do not generate distributable free cash flow in the conventional sense. Operating cash flow of -$147.78 billion captures regulatory liquidity requirements, loan growth funding, and deposit movements—not operational failure. We disregard this output and construct an earnings-based valuation framework.

WACC of 10.1% is reasonable for a G-SIB, incorporating 0.94 beta, 4.25% risk-free rate, and 5.5% equity risk premium. The 9.4% cost of equity appropriately captures JPM's lower systematic risk versus the market. However, terminal growth assumptions are problematic for financials; we use 3.0% terminal growth as a conservative long-run nominal GDP proxy.

Competitive advantage assessment: JPM exhibits position-based competitive advantage through customer captivity (corporate banking relationships, deposit franchise) and economies of scale (lowest unit costs in G-SIB peer set). This supports maintaining current 31.3% net margins versus industry mean-reversion, provided technology spend generates operating leverage. The $15B+ annual technology investment [strategic framing] must demonstrate ROI through deposit growth and efficiency gains to justify premium multiples. Without this capability-based advantage converting to position-based captivity, margins compress toward 28-29% peer averages.

Base case earnings projection: $20.02 EPS (2025) growing at 4% annually through 2029, reflecting normalized revenue growth (+3-4%), stable net margins (30-31%), and continued capital return. This yields Gordon growth fair value of $315 and residual income value of $305, bracketing our probability-weighted target.

Bear Case
$235
Credit cycle deterioration drives net charge-offs to 75bps, compressing net margin to 28%. Investment banking revenue falls 15% on deal flow collapse. P/B compresses to 1.75x on ROE decline to 12%. CCAR 2026 restricts buybacks to $15B. EPS drops to $18.50 in 2026.
Base Case
$298
Soft landing achieved with Fed funds rate stabilizing 3.5-4.0%. Revenue grows 4% annually, net margin holds 30-31%. Investment banking normalizes, offsetting NIM pressure. ROTCE sustains 15%+, supporting 2.0x P/B. $25B annual capital return continues. EPS reaches $21 by 2027.
Bull Case
$355
M&A and IPO markets rebound sharply; investment banking revenue up 25%. Deposit beta remains contained, NIM expands 10bps. Technology spend generates visible operating leverage, efficiency ratio improves 200bps. P/B expands to 2.4x on 17% ROE. EPS reaches $23 by 2027.
Super-Bull
$410
Rate cuts stimulate credit demand without impairing yields. JPM gains 200bps market share in corporate banking via First Republic integration success. Wealth management inflows accelerate; AUM grows 15% annually. P/B reaches 2.7x on 18% ROE. EPS exceeds $25 by 2027.

reverse dcf: what the market implies

market implied

The $283.44 market price implies specific expectations that we can reverse-engineer. Using a Gordon growth framework with 9.4% cost of equity, the market embeds approximately 3.5% terminal growth and assumes $20.02 base earnings are sustainable with modest growth. This is reasonable but not conservative.

Implied FCF margin of 31.3% matches current net margin, suggesting the market expects no mean reversion. For a bank, this is aggressive—historical net margins for money-center banks cluster 25-28%. The 300+ basis point premium to history requires continuous execution on technology-driven efficiency and pricing power.

The implied ROTCE is 15%+, consistent with current 15.7% ROE. This is the critical assumption: if JPM cannot sustain mid-teens returns on tangible equity, the 2.1x P/B multiple compresses toward 1.5-1.7x peer averages, implying 20-30% downside. The market is pricing JPM as a structurally superior franchise, not a cyclically elevated one.

Reasonableness assessment: The implied expectations are achievable but demanding. They require: (1) no credit cycle deterioration through 2027, (2) successful technology ROI conversion to operating leverage, (3) continued G-SIB regulatory forbearance on capital requirements, and (4) investment banking recovery without trading volatility collapse. Each assumption has 60-70% individual probability; combined, perhaps 40-45% joint probability. This suggests the market price embeds optimism, not exuberance.

Target $298 vs. fair value range $235-$410. The probability-weighted target sits 5.1% above current price, offering modest upside with balanced risk-reward. The gap to analyst consensus ($330-$345) reflects our higher probability weight on bear/base cases (70% combined) versus sell-side optimism. Conviction level: 60/100—quality franchise at fair price, not compelling discount. Position: NEUTRAL/HOLD for new capital; existing holders should trim on strength above $310.
Bull Case
$408.00
Soft landing sustains NII at $95B+, credit costs remain benign below 50bps, and JPM executes $25B+ annual buybacks; ROTCE expands to 19% and multiple re-rates to 13x forward EPS, driving stock to $380+ (35% upside) as the bank consolidates share in weakened competitor markets.
Base Case
$285.00
Moderate growth environment with NII stabilizing ~$90B, credit costs normalizing to 55-60bps, and ROTCE sustaining 16-17%; JPM returns $20B+ annually via buybacks/dividends, growing TBVPS 8% annually. Stock earns 12x $28 EPS = $336, plus dividends, delivering ~22% total return.
Bear Case
$200
Hard recession drives unemployment to 6.5%, net charge-offs surge to 75bps+, and NII falls to $85B; combined with aggressive Basel III implementation, ROTCE compresses to 13% and stock trades to 9x earnings on $22 EPS, implying ~$200 (30% downside) with book value growth stalled.
mc median
$250
10,000 simulations
mc mean
$250
5th percentile
$250
downside tail
95th percentile
$250
upside tail
p(upside)
0%
vs $286.56
Exhibit 1: Intrinsic Value Methods Comparison
method fair value vs current key assumption reliability
p/e multiple (14x) $280 -2.3% 2026 eps $20.00, peer avg multiple HIGH
p/b multiple (2.0x) $268 -6.5% tangible book ~$134, slight premium compression… HIGH
gordon growth model $315 +9.9% $20.02 base eps, 4% growth, 9.4% coe MEDIUM
residual income model $305 +6.4% 15.7% roe, 3% growth, 9.4% coe MEDIUM
reverse dcf (market implied) $283 -1.2% implies 3.5% terminal growth, 10.1% wacc… benchmark
dcf (standard fcf) $265 -7.5% model misspecified for banks—disregard not applicable
metric value
pe $855.91
cash flow $147.78 billion
wacc of 10.1%
+ annual technology investment $15b
fair value $315
fair value $305
Exhibit 2: Peer Valuation Comparison
company p/e p/s revenue growth net margin roe
jpmorgan chase (jpm) 14.2x 4.2x +2.8% 31.3% 15.7%
bank of america (bac) ~12.0x ~2.8x ~25% ~11%
citigroup (c) ~16.0x ~1.5x ~18% ~8%
wells fargo (wfc) ~14.0x ~2.2x ~22% ~10%
goldman sachs (gs) ~13.0x ~3.0x ~20% ~12%
morgan stanley (ms) ~14.0x ~3.5x ~24% ~13%
Exhibit 3: Mean Reversion Analysis
metric current 5yr mean std dev implied value reversion signal
p/e ratio 14.2x ~13.0x ~1.5x $260 CAUTION mild overvalued
p/b ratio 2.1x ~1.6x ~0.4x $215 ELEVATED overvalued
net margin 31.3% ~28.0% ~2.5% $255 CAUTION above trend
roe 15.7% ~13.5% ~2.0% $295 SUPPORTED sustainable
ev/revenue 4.1x ~3.2x ~0.8x $220 ELEVATED

Scenario Weight Sensitivity

25
45
25
5
Total: —
Probability-Weighted FV
Upside/Downside
Exhibit: WACC Derivation (CAPM)
component value
beta 0.94
risk-free rate 4.25%
equity risk premium 5.5%
cost of equity 9.4%
d/e ratio (market-cap) 0.44
dynamic wacc 10.1%
Exhibit: Kalman Growth Estimator
metric value
current growth rate 9.2%
growth uncertainty ±14.6pp
observations 13
year 1 projected 7.9%
year 2 projected 6.8%
year 3 projected 6.0%
year 4 projected 5.3%
year 5 projected 4.7%
monte carlo fair value range
valuation multiples
Current Price
283.44
DCF Adjustment ($265)
1139.35
MC Median ($250)
496.27
Biggest valuation risk: P/B multiple compression on ROE disappointment. The 2.1x P/B assumes 15.7% ROE persists; if 2026 stress tests or credit normalization compress ROE to 12%, fair value drops to ~$215 (-24%). The $140B Q4 2025 balance sheet contraction ($4.56T to $4.42T) may signal early deposit pressure or active liquidity management—monitor Q1 2026 for trend confirmation.
Mean reversion signals are mixed. P/B at 2.1x sits 1.25 standard deviations above 5-year mean, suggesting 15-20% downside risk if premium compresses. However, ROE of 15.7% is only 1.1 standard deviations above trend, indicating the earnings power justifies elevated multiples. The divergence between book-based and earnings-based reversion signals reflects JPM's successful shift toward higher-ROE businesses (asset management, investment banking) and technology-driven efficiency.
1 finding(s) removed during verification due to unsupported claims (impossible_financial).
price / earnings
14.2x
fy2025
price / book
2.1x
fy2025
price / sales
4.2x
fy2025
ev/rev
4.1x
fy2025
JPM commands a 60-100% P/B premium to money-center peers. The 2.1x P/B reflects 15.7% ROE against 9.4% cost of equity—a 630 basis point spread that creates genuine economic value. This spread exceeds BAC (~200 bps), C (negative), and WFC (~100 bps), justifying the quality premium. On P/E (14.2x), JPM trades in-line with peers (BAC ~12x, C ~16x, WFC ~14x), indicating the premium is concentrated in franchise value rather than earnings multiples. The ROE spread has compressed from peak 2022-2023 levels when rate hikes supercharged NIM.
JPM's 2.1x P/B premium is justified by 630bps ROE-COE spread, but the spread is compressing—2025 net income fell -2.4% despite +2.8% revenue growth, and Q4 implied EPS of ~$4.60 was down sequentially from Q3's $5.07. This is neutral-to-cautious for the thesis: the bank is executing well but cycling from exceptional to normal. We would turn bullish on a pullback to $250-260 (13x P/E, 1.9x P/B) or evidence that technology spend is driving deposit share gains versus BAC/WFC. We would turn bearish on ROE compression below 14% or CCAR restrictions limiting buybacks to <$20B annually.
See financial analysis
See competitive position
See risk assessment